Scan to check prostate cancer response after focused radiation
Treatments studied
Part of Cancer clinical trials.
This study tests whether a special PET scan tracer (18F-DCFPyL) can show how well focused radiation (SBRT) is working for localized prostate cancer. It may help doctors spot treatment response earlier and tailor follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven prostate cancer that has not spread beyond the prostate/seminal vesicles
- Your treatment plan includes SBRT for the prostate (with or without hormone-blocking pills like ADT)
- You must have at least one prostate MRI finding that the study can use
- You’re age 18 or older, and your health status is not severely limited (ECOG 2 or less)
- You can be safely scanned: you fit on the scanner table (not over 350 lbs) and can tolerate the radiation/SBRT plan
- If you have HIV/HBV/HCV, your virus levels must be controlled/undetectable on treatment (as applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET/MRI scan (using a tracer called 68Ga-PSMA-11) can better identify the main tumor in men with early prostate cancer who are planning surgery. The goal is to help doctors target treatment more precisely in the future.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
This study checks how your immune system’s cancer-fighting cells change after stereotactic body radiation (SBRT) to the prostate. It compares SBRT alone versus SBRT plus an immunotherapy drug (PDS01ADC) in men with intermediate- or high-risk localized prostate cancer treated with hormone therapy (ADT).
This trial tests a new PET scan (a type of imaging that uses a radioactive tracer) to see how well it can find prostate cancer after focal therapy. If you join, you'll get the scan before and after your treatment to help doctors see if any cancer is left.
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.